Add 2 More Reports For 20% off

Report Overview

The global genomics market size was valued at USD 38.1 billion in 2023, driven by increased funding for genomic projects and the prevalence of chronic diseases across the globe. The market is expected to grow at a CAGR of 15.6% during the forecast period of 2024-2032, with the values likely to rise from USD 44 billion in 2024 to USD 140.1 billion by 2032.

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Genomics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Genomics Market Overview

Genomics attempts to understand the genetic makeup of an organism and the downstream biological products. This branch of biology has emerged as the most impactful industry trend to treat and prevent diseases. The market demand is driven by multiple factors such as the increased demand for personalized medicine, gene therapy, and the prevalence of chronic diseases like cancer. A study published in Nature Medicine in January 2024  revealed that integrating clinical data with whole genome sequence data can pave the way for precision oncology. Consequently, it would help doctors provide customized treatment plans to patients suffering from cancer, leading to better patient outcomes.

The robust research activities have resulted in the development of a genomic data pool. This data can be utilized by physicians and biologists to find the genetic predisposition to certain diseases. It is expected that the clinical implementation of this genetic data pool will fuel the genomics market growth along with the evolution of a healthcare system that is more tailored to the patient’s needs.

Growth of Genome Editing-Based Therapeutics

The clinical application of genomics can improve the diagnostics system as well as provide personalized treatment options. The recent technological advancements in treatments, employing genomic editing holds the potential to improve the lives of many individuals. In January 2023, CAR-T cell therapy,  which works by using genetically modified T cells to identify and destroy specific cancer cells, cured a 13-year-old patient suffering from leukaemia.

The surge in approvals by the regularity authorities has further amplified the genomics market share. In November 2023, the UK Medicines and Health Regulatory Authority (MHRA)  approved a CRISPR-based gene therapy known as Casgevy or Exa-cel. This genome-edited cellular therapy utilizes the CRISPR/Cas9 system to produce healthy red blood cells in people with beta-thalassemia and sickle cell disease.

Increased Research Breakthroughs in Genomics

The growing research and clinical trials in the field of genomics, aided by increased funding and technological advancements have led to major research breakthroughs. In August 2023, a research article published in Nature revealed that scientists completed the sequencing of the human Y chromosome. It led to an addition of 30 million new bases in the human genome reference by end-to-end sequencing. The new research is poised to facilitate a better understanding of variation and associated diseases, offering improved therapeutic solutions to critical ailments.

Strategic Investments to Meet Genomics Market Demand

The rising investments by biotechnology firms to accelerate genomic research is expected to reflect significant implications in reshaping the market. In February 2023, Accenture Ventures  made a strategic investment in Ocean Genomics, a technology and AI company based in the United States to assist biopharma companies by creating computational platforms. The investment is expected to expedite the development of personalized medicines and artificial intelligence driven drug discovery. The incorporation of technological and scientific advancements in the healthcare system is anticipated to result in improved therapeutics and diagnostics fuelling the market growth.

Global Genomics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Genomics Market Segmentation

“Genomics Market Report and Forecast 2024-2032” offers a detailed analysis of the market based on the following segments:

Market Breakup by Deliverables

  • Product
  • Software and Services

Market Breakup by Technology

  • Sequencing
  • Microarray
  • Polymerase Chain Reaction (PCR)
  • Nucleic Acid Extraction
  • Purification
  • Others

Market Breakup by Process

  • Library Preparation
  • Data Analysis
  • Others

Market Breakup by Application

  • Epigenomics
  • Functional
  • Biomarker Discovery
  • Pathway Analysis
  • Diagnostics
  • Drug Discovery
  • Development
  • Precision Medicine
  • Agriculture
  • Animal Research
  • Others

Market Breakup by End Users

  • Government and Academic Institutes
  • Clinical Research
  • Healthcare Facilities
  • Biotechnology and Pharmaceutical Companies
  • Others

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Global Genomics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Genomics Market Regional Analysis

In North America, the robust healthcare system and increased funding for genomic projects are pushing the market growth. The prevalence of health issues in the region such as cancer, fuels the demand for genomic research in diagnostics and personalized medicine further. As a result, several pharmaceutical companies are collaborating or forming strategic alliances to deliver improved products and services to patients.

Europe holds a significant genomics market share which can be attributed to the existence of major research institutes and healthcare companies that play a pivotal role in increasing the market size.

The growing approvals of gene therapy treatments by health authorities and the evolving preference of patients for minimally invasive treatment procedures have further aided the market growth. In January 2024, Qiagen , a multinational provider of molecular testing solutions based in Germany, received the United States Food and Drug Administration (FDA) approval for NeuMoDx CT/NG Assay employing integrated PCR-based clinical molecular testing system, NeuMoDx 96 and 288 Molecular Systems. This assay utilizing fully automated analysers is designed to provide a rapid and precise diagnosis of sexually transmitted infection (STI).

Global Genomics Market: Competitor Landscape

In January 2024, Veracyte,  a global diagnostics company headquartered in the United States, acquired C2i Genomics, a biotechnology company based in Israel known for its minimal residual disease (MRD) tests in a USD 95 million deal. This acquisition aims to employ AI-assisted whole-genome MRD tests to expand the cancer diagnostics range. Thus, the boost in genomic research is supported by major investments in acquisitions, mergers, and expansions by the top biotechnology firms. Consequently, the genomics market value is expected to witness a surge in the forecast period.

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

  • Eppendorf SE
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Freenome Holdings, Inc.
  • Myriad Genetics
  • Oxford Nanopore Technologies
  • PacBio
  • QIAGEN
  • Thermo Fisher Scientific
  • 23andMe
  • FOUNDATION MEDICINE
  • IntegraGen
  • Genome Diagnostics Pvt. Ltd
  • Cytiva

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Genomics Market Report Snapshots

Genomics Market Size

Genomics Analysis

Genomics Companies

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The market attained a value of about USD 38.1 billion in 2023 driven by increased funding for genomic projects and the prevalence of chronic diseases across the globe.

The market is anticipated to grow at a CAGR of 15.6% during the forecast period of 2024-2032, likely to reach a market value of USD 140.1 billion by 2032.

The market demand is driven by the increasing prevalence of chronic diseases and the surge in funding and investments in research and development activities in the field of genomics.  

The development in minimally invasive cancer screening-based research and growing clinical trials are some of the key trends in the genomics market. In January 2024, Veracyte, a global diagnostics company acquired an Israel-based biotechnology company, C2i Genomics, to expand its cancer diagnostics range.

Product, software and services are major deliverables.

Based on the technology type, the market is divided into sequencing, microarray, polymerase chain reaction (PCR), nucleic acid extraction, purification, and others.

It includes library preparation, and data analysis among others.

Common application areas include epigenomics, functional, biomarker discovery, pathway analysis, diagnostics, drug discovery and development, precision medicine, agriculture, animal research and others. 

The various end users include government and academic institutes, clinical research centers, healthcare facilities, pharmaceutical and biotechnology companies, among others.

The major regions of the market include North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.

Key players involved in the market are Eppendorf SE, Eurofins Scientific, F. Hoffmann-La, Roche Ltd, GE Healthcare, Freenome Holdings, Inc., Myriad Genetics, Oxford Nanopore Technologies, PacBio, QIAGEN, Thermo Fisher Scientific, 23andMe, FOUNDATION MEDICINE, IntegraGen, Genome Diagnostics Pvt. Ltd and Cytiva.

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Deliverables
  • Technology
  • Process
  • Application
  • End Users
  • Region
Breakup by Deliverables
  • Product
  • Software and Services
Breakup by Technology
  • Sequencing
  • Microarray
  • Polymerase Chain Reaction (PCR)
  • Nucleic Acid Extraction
  • Purification
  • Others
Breakup by Process
  • Library Preparation
  • Data Analysis
  • Others
Breakup by Application
  • Epigenomics
  • Functional
  • Biomarker Discovery
  • Pathway Analysis
  • Diagnostics
  • Drug Discovery
  • Development
  • Precision Medicine
  • Agriculture
  • Animal Research
  • Others
Breakup by End Users
  • Government and Academic Institutes
  • Clinical Research
  • Healthcare Facilities
  • Biotechnology and Pharmaceutical Companies
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Eppendorf SE
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Freenome Holdings, Inc.
  • Myriad Genetics
  • Oxford Nanopore Technologies
  • PacBio
  • QIAGEN
  • Thermo Fisher Scientific
  • 23andMe
  • FOUNDATION MEDICIN
  • IntegraGen
  • Genome Diagnostics Pvt. Ltd
  • Cytiva

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,499

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,699

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,599

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,599

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124